Udhayvir Grewal, Resident Physician at Ochsner LSU Health Shreveport, Medical Oncologist at Winship Cancer Institute at Emory Midtown, shared a post on X:
“Thank you Neuroendocrine Cancer Research Foundation, Anna Greene for the opportunity to write this guest blog post for updates in Neuroendocrine Cancer research presented at ASCO26.
- Alpha RLT – Early phase data with ²¹²Pb-VMT-α-NET showed a 39% ORR with minimal marrow/renal toxicity, reinforcing the promise of alpha-emitting radioligand therapy.
- DLL3 (the target we’re all excited about in high grade NENs) – The trispecific T-cell engager alveltamig (ZG006) achieved up to 56% ORR in DLL3-high refractory NEC. Excited to see this moving along.
- CAR-T enters the NET space! Early feasibility data with CDH17-directed CAR-T (CHM-2101) showed successful manufacturing, expansion, and manageable toxicity in GI cancers including intestinal NETs. (Dr. Jen Eads) – trial also open at Winship Cancer Institute of Emory University.
- MTAP loss in NETs? Unexpectedly high MTAP deficiency across PanNETs and small bowel NETs, reported by Rohit Thummalapalli. Room for PRMT5i/MAT2Ai in NETs?
- Long-term PRRT safety data matter – In >1,800 patients treated with Lu-177 DOTATATE, overall risk for therapy-related MDS/AML remained low (2.9%) but there is a genuine need for better risk stratification.”
Udhayvir Grewal, Cancer, OncoDaily, Oncology
Other articles featuring Udhayvir Grewal on OncoDaily.